- Merck & Co. Inc. and Ridgeback Biotherapeutics LP said their COVID-19 antiviral pill, molnupiravir, was active against the Omicron variant in six lab studies. The drug’s effectiveness against Omicron hasn’t yet been studied in human trials. (Article here)
January 28, 2022
Life Sciences